Effect of danazol in immune thrombocytopenic purpura.
Danazol and vinblastine are effective in many patients with chronic immune thrombocytopenic purpura (ITP). To evaluate the mechanism of action of these drugs, we studied six consecutive patients with chronic ITP treated with danazol and one treated with vinblastine. All the patients responded clinically without a notable change in the level of platelet-associated IgG. Instead, the clinical response to therapy was associated with a decrease in the number of monocyte binding sites for monomeric IgG (Fc receptors). In one patient, clinical relapse was associated with a spontaneous 2.7-fold increase in the number of monocyte Fc (IgG) receptors, without a change in the level of platelet-associated immunoglobulin. A decrease in the number of monocyte Fc (IgG) receptors following vinblastine infusion was associated with a clinical remission. We conclude that the clinical course of ITP may be influenced by the expression of monocyte or macrophage Fc (IgG) receptors. Danazol and vinblastine may mediate their clinical effect, at least in part, by influencing the number of available Fc (IgG) receptors on phagocytic cells.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology; D003613:Danazol / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D010586:Phagocytes / Q000187:drug effects / Q000276:immunology; D011245:Pregnadienes / Q000627:therapeutic use*; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy* / Q000276:immunology; D011961:Receptors, Fc / Q000032:analysis / Q000187:drug effects*; D014747:Vinblastine / Q000494:pharmacology / Q000627:therapeutic use
D007074:Immunoglobulin G; D011245:Pregnadienes; D011961:Receptors, Fc; D014747:Vinblastine; D003613:Danazol